Associated Papers
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
ctDNA as a Molecular Biomarker in the Phase II Trial of Imatinib plus Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumor.
Kelly CM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Pathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges.
Sotiropoulou CD et al.
European Journal of Haematology, 2025
Novel KIT mutation, D816_N819delinsll, in a patient with systemic mastocytosis: a case report.
Juratli HA et al.
Virchows Archiv : an International Journal of Pathology, 2025
Computational modeling of human genetic variants in mice.
Dong K et al.
Biorxiv : the Preprint Server for Biology, 2025
Clinical and Biological Characteristics of Four Patients with Aggressive Systemic Mastocytosis Treated with Midostaurin.
Soare D et al.
Biomedicines, 2025
Clinicopathological characteristics of progressive gastrointestinal stromal tumors and heterogeneity analyses of secondary mutations.
Li J et al.
The Oncologist, 2025
Clinical Use of Liquid-Based Comprehensive Genomic Profiling in Gastrointestinal Stromal Tumors.
Mechahougui H et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology, 2025
Patient-derived xenograft models of gastrointestinal stromal tumors provide a ready-to-use platform for translational research.
De Sutter L et al.
Disease Models & Mechanisms, 2025
Novel structural variants that impact cell cycle genes are elucidated in metastatic gastrointestinal stromal tumors.
Delgado-de la Mora J et al.
Pathology, Research and Practice, 2025
Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital.
Kim JW et al.
Scientific Reports, 2025
Case Report: Dramatic response to entritinib in a patient with gastrointestinal stromal tumor positive for NTRK3 fusion.
Dong G et al.
Frontiers in Oncology, 2025
Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research.
Cao L et al.
Global Medical Genetics, 2024
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature.
Filetti M et al.
Cancers, 2024
Longitudinal ultra-sensitive mutation burden sequencing for precise minimal residual disease assessment in AML.
Wu Y et al.
Nature Communications, 2024
MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study.
Cai X et al.
Bmc Cancer, 2024
Detection of KIT Mutations in Systemic Mastocytosis: How, When, and Why.
Cilloni D et al.
International Journal of Molecular Sciences, 2024
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C et al.
Signal Transduction and Targeted Therapy, 2024
Binary classification of copy number alteration profiles in liquid biopsy with potential clinical impact in advanced NSCLC.
Tosello V et al.
Scientific Reports, 2024
Novel molecular subtypes of intracranial germ cell tumors expand therapeutic opportunities.
Li B et al.
Neuro-oncology, 2024
Whole-exome sequencing has revealed novel genetic characteristics in intracranial germ cell tumours in the Chinese.
Huang X et al.
Histopathology, 2024
Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis.
Naumann N et al.
Cancers, 2024
Diagnosis, Treatment, and Prognosis of Patients with Primary Familial Gastrointestinal Stromal Tumor: A Case Report and Literature Review.
Yan M et al.
The Oncologist, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
McCarter JGW et al.
Blood Advances, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).
De Sutter L et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Next-Generation Sequencing-Based Genomic Profiling of Children with Acute Myeloid Leukemia.
Krizsán S et al.
The Journal of Molecular Diagnostics : Jmd, 2023
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
Pardanani A
American Journal of Hematology, 2023
Deep genomic characterization highlights complexities and prognostic markers of pediatric acute myeloid leukemia.
Cheng CK et al.
Communications Biology, 2023
Novel Molecular Therapies and Genetic Landscape in Selected Rare Diseases with Hematologic Manifestations: A Review of the Literature.
Ręka G et al.
Cells, 2023
Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
Bhai P et al.
Frontiers in Oncology, 2023
c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights.
Abdellateif MS et al.
Oncotargets and Therapy, 2023
Gastrointestinal stromal tumors caused by novel germline variants in SDHB and KIT: a report of two cases and literature review.
Rasmussen S et al.
Clinical Journal of Gastroenterology, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn N et al.
Leukemia, 2022
Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.
El Hussein S et al.
Cancers, 2022
Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.
González-López O et al.
Cancers, 2022
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
Jeffers M et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022
Systematic review and meta-analysis of genomic alterations in acral melanoma.
Broit N et al.
Pigment Cell & Melanoma Research, 2022
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
Katagiri S et al.
International Journal of Molecular Sciences, 2022
Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers.
George S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification.
Liu T et al.
Nature Communications, 2022
Monitoring Circulating Tumor DNA During Surgical Treatment in Patients with Gastrointestinal Stromal Tumors.
Johansson G et al.
Molecular Cancer Therapeutics, 2021
Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy.
Zhang Y et al.
Cell Reports, 2021
Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test.
Tomlins SA et al.
The Journal of Molecular Diagnostics : Jmd, 2021
Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
Muñoz-González JI et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 2021
Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice.
Steeghs EMP et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021